{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T21:08:20Z","timestamp":1785186500915,"version":"3.55.0"},"reference-count":25,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2012,7,10]],"date-time":"2012-07-10T00:00:00Z","timestamp":1341878400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Endocrinology"],"published-print":{"date-parts":[[2012,8]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>An association between treatment for <jats:styled-content style=\"fixed-case\">P<\/jats:styled-content>arkinson's disease with certain dopaminergic drugs and development of cardiac valve impairment has been reported. Recent studies in hyperprolactinaemic patients treated with cabergoline (<jats:styled-content style=\"fixed-case\">CAB<\/jats:styled-content>) have shown either no significant findings or mild tricuspid regurgitation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To determine the prevalence of cardiac valve dysfunction in patients with hyperprolactinaemic conditions chronically treated with <jats:styled-content style=\"fixed-case\">CAB<\/jats:styled-content> or bromocriptine (<jats:styled-content style=\"fixed-case\">BR<\/jats:styled-content>).<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>Retrospective<jats:bold>,<\/jats:bold> multicentric, cross\u2010sectional study of cases <jats:italic>vs<\/jats:italic> controls.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients<\/jats:title><jats:p>Eighty\u2010three hyperprolactinaemic patients (15 men, 68 women aged 16\u00b77\u201363\u00a0years; 64% microprolactinomas, 28% macroprolactinomas and 8% other etiologies) from three <jats:styled-content style=\"fixed-case\">S<\/jats:styled-content>panish university hospitals chronically treated with <jats:styled-content style=\"fixed-case\">BR<\/jats:styled-content> (14\u2013562\u00b75\u00a0weeks, cumulative dose 5603\u00a0\u00b1\u00a07729\u00a0mg) or <jats:styled-content style=\"fixed-case\">CAB<\/jats:styled-content> (12\u2013765\u00a0weeks, 217\u00b74  \u00b1  306\u00b76\u00a0mg).<\/jats:p><\/jats:sec><jats:sec><jats:title>Measurements<\/jats:title><jats:p>Transthoracic echocardiographic assessment of valvular regurgitation and thickening, mitral valve tenting area and left\u2010ventricular ejection fraction from 83 patients were compared with results from 58 age\u2010 and sex\u2010matched controls and correlated with cumulative doses of dopaminergic drugs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>No significant differences in valvular regurgitation, valve thickness or any other echocardiographic parameter were observed between controls and patients, except for 15 patients in the higher quartile of <jats:styled-content style=\"fixed-case\">CAB<\/jats:styled-content> cumulative dose (&gt;180\u00a0mg), with increased prevalence of mild tricuspid regurgitation (6\/15, 40% <jats:italic>vs<\/jats:italic> 8\/58, 13\u00b78%, <jats:italic>P<\/jats:italic>\u00a0=\u00a00\u00b7024; <jats:styled-content style=\"fixed-case\">OR<\/jats:styled-content> 4\u00b71; 1\u00b71\u201314\u00b79). High <jats:styled-content style=\"fixed-case\">BR<\/jats:styled-content> cumulative dose was associated with no significant findings.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>No increased valvular involvement was found after long\u2010term dopaminergic therapy for hyperprolactinaemia except for a significant increase in mild tricuspid regurgitation associated with high cumulative doses of <jats:styled-content style=\"fixed-case\">CAB<\/jats:styled-content>;<jats:styled-content style=\"fixed-case\"> BR<\/jats:styled-content> seems spared from this adverse effect, although the low number of cases limits this analysis. Cumulative dose registry and long\u2010term studies are warranted to definitely clarify this item.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1365-2265.2012.04349.x","type":"journal-article","created":{"date-parts":[[2012,1,30]],"date-time":"2012-01-30T19:27:37Z","timestamp":1327951657000},"page":"275-280","source":"Crossref","is-referenced-by-count":32,"title":["No clinically significant valvular regurgitation in long\u2010term cabergoline treatment for prolactinoma"],"prefix":"10.1111","volume":"77","author":[{"given":"Irene","family":"Halperin","sequence":"first","affiliation":[{"name":"Servicio de Endocrinolog\u00eda y Nutrici\u00f3n"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Aller","sequence":"additional","affiliation":[{"name":"Servicio de Endocrinolog\u00eda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9sar","family":"Varela","sequence":"additional","affiliation":[{"name":"Servicio de Endocrinolog\u00eda Hospital Ram\u00f3n y Cajal  Madrid"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireia","family":"Mora","sequence":"additional","affiliation":[{"name":"Servicio de Endocrinolog\u00eda y Nutrici\u00f3n"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ainhoa","family":"Abad","sequence":"additional","affiliation":[{"name":"Servicio de Endocrinolog\u00eda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ada","family":"Doltra","sequence":"additional","affiliation":[{"name":"Servicio de Cardiolog\u00eda Hospital Cl\u00ednic Universitat de Barcelona  Barcelona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia Estrella","family":"Santos","sequence":"additional","affiliation":[{"name":"Servicio de Endocrinolog\u00eda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Batista","sequence":"additional","affiliation":[{"name":"Servicio de Endocrinolog\u00eda Hospital Sagrado Coraz\u00f3n"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Garc\u00eda\u2010Pav\u00eda","sequence":"additional","affiliation":[{"name":"Servicio de Cardiolog\u00eda Hospital Universitario Puerta de Hierro"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Sitges","sequence":"additional","affiliation":[{"name":"Servicio de Cardiolog\u00eda Hospital Cl\u00ednic Universitat de Barcelona  Barcelona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas G.","family":"Mirelis","sequence":"additional","affiliation":[{"name":"Servicio de Cardiolog\u00eda Hospital Universitario Puerta de Hierro"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom\u00e1s","family":"Lucas","sequence":"additional","affiliation":[{"name":"Servicio de Endocrinolog\u00eda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manel","family":"Puig\u2010Domingo","sequence":"additional","affiliation":[{"name":"Servicio de Endocrinolog\u00eda Hospital Germans Tr\u00edas i Pujol  Badalona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,7,10]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199708283370901"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.102.23.2836"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp068265"},{"key":"e_1_2_5_5_1","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1517\/14740330902931524","article-title":"Serotoninergic drugs and valvular heart disease","volume":"8","author":"Rothman R.B.","year":"2000","journal-title":"Expert Opinion on Drug Safety"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2006.08.004"},{"key":"e_1_2_5_7_1","first-page":"9","article-title":"Valvular heart disease and the use of dopamine agonists for Parkinson's disease","volume":"3","author":"Zanettini R.","year":"2007","journal-title":"New England Journal of Medicine"},{"key":"e_1_2_5_8_1","first-page":"9","article-title":"Dopamine agonists and the risk of cardiac\u2010valve regurgitation","volume":"2","author":"Schade R.","year":"2007","journal-title":"New England Journal of Medicine"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-2095"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-1403"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2008.01779.x"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.4158\/EP.14.6.672"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-2658"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-08-0213"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-08-0365"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2008.03458.x"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-008-0134-2"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2009.03608.x"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1067\/mje.2002.120202"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22228"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22385"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2010.03827.x"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-1692"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022657"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(98)01064-9"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-8703(89)90739-4"}],"container-title":["Clinical Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2265.2012.04349.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2265.2012.04349.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T16:36:39Z","timestamp":1698770199000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2265.2012.04349.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,10]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["10.1111\/j.1365-2265.2012.04349.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2265.2012.04349.x","archive":["Portico"],"relation":{},"ISSN":["0300-0664","1365-2265"],"issn-type":[{"value":"0300-0664","type":"print"},{"value":"1365-2265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7,10]]}}}